Bart Van Wijmeersch (Belgium)
Universitair MS Centrum (UMSC), Rehabilitation & MS Centre Pelt, Hasselt University TBAAssociate Professor Bart Van Wijmeersch is a neurologist specialised in multiple sclerosis (MS). He is the medical director of the University MS Centre in Pelt, where he leads the multidisciplinary MS team. He is also associate professor of Neurology at the University of Hasselt where he is involved in preclinical and clinical MS research at the Biomedical Institute (BIOMED/REVAL). Additionally, Prof Van Wijmeersch has an educational role in the Faculty of Medicine and Physiotherapy. He is a member of the Belgian Study Group of MS and was a co-founder and the first president of the ParadigMS Foundation, an organisation dedicated to MS education to help improve clinical care for MS patients. In 2019, he received an honorary award from the Flemish government to acknowledge his scientific work.
Author Of 1 Presentation
Sponsored Symposium
Subcutaneous natalizumab: clinical trial outcomes and experience
Session Type
Sponsored Symposium
Session Name
Date
03.10.2021, Sunday
Session Time
14:00 - 15:10
Room
Industry 2
Lecture Time
14:18 - 14:31
Presenter
- Bart Van Wijmeersch (Belgium)
Presenter of 2 Presentations
Sponsored Symposium
Closing remarks and live Q&A
Session Type
Sponsored Symposium
Session Name
Date
03.10.2021, Sunday
Session Time
14:00 - 15:10
Room
Industry 2
Lecture Time
14:44 - 15:10
Presenter
- Bart Van Wijmeersch (Belgium)
- Paolo Gallo (Italy)
- Boris-Alexander Kallmann (Germany)
Sponsored Symposium
Subcutaneous natalizumab: clinical trial outcomes and experience
Session Type
Sponsored Symposium
Session Name
Date
03.10.2021, Sunday
Session Time
14:00 - 15:10
Room
Industry 2
Lecture Time
14:18 - 14:31
Presenter
- Bart Van Wijmeersch (Belgium)
Moderator of 1 Session
Sponsored Symposium
Session Time
14:00 - 15:10
Room
Industry 2
Chair(s)
- Bart Van Wijmeersch (Belgium)
- Massimo Filippi (Italy)
Session Description
Advancing MS Care: A New Opportunity in High Efficacy Therapy
Join this symposium to learn about the key data that have led to the EMA approval of the subcutaneous use of natalizumab, gain practical insights into using this new route of administration in clinical practice, and keep up-to-date on the latest evidence to maximize the safe, effective use of natalizumab.
The faculty will provide three presentations on the latest advances in treatment with natalizumab followed by a live question-and-answer session. During the session, the online audience can ask questions to the expert panel.